Seaport Therapeutics, Inc. Common Stock (SPTX) - Net Assets
Based on the latest financial reports, Seaport Therapeutics, Inc. Common Stock (SPTX) has net assets worth $422.60 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($441.68 Million) and total liabilities ($19.08 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See Seaport Therapeutics, Inc. Common Stock (SPTX) balance sheet quality index to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $422.60 Million |
| % of Total Assets | 95.68% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Seaport Therapeutics, Inc. Common Stock - Net Assets Trend (2024–2025)
This chart illustrates how Seaport Therapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Seaport Therapeutics, Inc. Common Stock (SPTX) market capitalisation.
Annual Net Assets for Seaport Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual net assets of Seaport Therapeutics, Inc. Common Stock from 2024 to 2025. Also explore how fast is Seaport Therapeutics, Inc. Common Stock growing its equity to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-92.55 Million | -272.43% |
| 2024-12-31 | $-24.85 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Seaport Therapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7488100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | % |
| Other Comprehensive Income | $301.00K | % |
| Other Components | $21.26 Million | % |
| Total Equity | $-92.55 Million | 100.00% |
Seaport Therapeutics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Seaport Therapeutics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhejiang Fulai New Material Co.Ltd.
SHG:605488
|
$1.23 Billion |
|
Capital Clean Energy Carriers Corp.
NASDAQ:CCEC
|
$1.23 Billion |
|
Berkshire Hills Bancorp Inc
NYSE:BHLB
|
$1.23 Billion |
|
Hannstar Display Corp
TW:6116
|
$1.23 Billion |
|
Adriatic Metals Plc
F:3FN
|
$1.23 Billion |
|
Kestra Medical Technologies, Ltd. Common Stock
NASDAQ:KMTS
|
$1.23 Billion |
|
Shandong Weigao Orthopaedic Device Co. Ltd. A
SHG:688161
|
$1.23 Billion |
|
Taiji Computer Corp Ltd
SHE:002368
|
$1.23 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Seaport Therapeutics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -24,849,000 to -92,545,000, a change of -67,696,000.
- Net loss of 74,881,000 reduced equity.
- Other comprehensive income increased equity by 301,000.
- Other factors increased equity by 6,884,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-74.88 Million | -80.91% |
| Other Comprehensive Income | $301.00K | +0.33% |
| Other Changes | $6.88 Million | +7.44% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Seaport Therapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2024-12-31 | $-0.47 | $22.96 | x |
| 2025-12-31 | $-2.39 | $22.96 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Seaport Therapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-44.39 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-65.63 Million |
Industry Comparison
This section compares Seaport Therapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,895,707
- Average return on equity (ROE) among peers: -42.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Seaport Therapeutics, Inc. Common Stock (SPTX) | $422.60 Million | 0.00% | 0.05x | $1.23 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $109.30 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $170.10 Million | -16.06% | 0.05x | $310.51 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-12.35 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.35 Billion |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.31 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $199.76 Million | -82.32% | 0.11x | $4.61 Billion |
About Seaport Therapeutics, Inc. Common Stock
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-30… Read more